2-methoxycyclopentanamine | 954582-89-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-methoxycyclopentanamine
• 英文别名: trans-2-methoxycyclopentylamine；2-Methoxycyclopentan-1-amine
• CAS: 954582-89-9
• 化学式: C₆H₁₃NO
• mdl: MFCD09742740
• 分子量: 115.175
• InChiKey: PRXWOOCEFBBQCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-methoxycyclopentanamine 、 4,8-二氯吡啶并[3,4-D]嘧啶 在 N,N-二异丙基乙胺 作用下， 反应 20.0h， 生成
  参考文献：
  名称：

  Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors

  摘要：

  A highly ligand efficient, novel 8-oxo-pyridopyrimidine containing inhibitor of Jak1 and Jak2 isoforms with a pyridone moiety as the hinge-binding motif was discovered. Structure-based design strategies were applied to significantly improve enzyme potency and the polarity of the molecule was adjusted to gain cellular activity. The crystal structures of two representative inhibitors bound to Jak1 were obtained to enable SAR exploration. (C) 2013 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2013.08.082
• 作为产物：
  描述：

  benzyl trans-(2-methoxycyclopentyl) carbamate 生成 2-methoxycyclopentanamine
  参考文献：
  名称：

  BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVE AND USE THEREOF

  摘要：

  提供了化合物(I)的配方，或其药物可接受的盐、溶剂合物、活性代谢物、多晶形、同位素标记、异构体或前药，以及其用途。上述化合物对FGFR4激酶活性和具有高FGFR4表达的Hep 3B细胞的增殖活性具有非常强的抑制作用。

  公开号：

  EP4053126A1

文献信息

• 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF
  申请人：Genentech, Inc.

  公开号：US20200108075A1

  公开（公告）日：2020-04-09

  3-Carbonylamino-8-aminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylamino-8-aminoisoquinoline compounds.

  公式（I）的3-羰基氨基异喹啉化合物及其变体，以及它们作为HPK1（造血激酶1）抑制剂的用途被描述。这些化合物在治疗HPK1依赖性疾病和增强免疫应答方面是有用的。还描述了抑制HPK1的方法，治疗HPK1依赖性疾病的方法，增强免疫应答的方法，以及制备3-羰基氨基异喹啉化合物的方法。
• [EN] USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI<br/>[FR] UTILISATION D'OXADIAZOLES SUBSTITUÉS POUR LUTTER CONTRE DES FONGUS PHYTOPATHOGÈNES
  申请人：BASF SE

  公开号：WO2015185485A1

  公开（公告）日：2015-12-10

  The present invention relates to the use of novel oxadiazoles of the formula I or an N- oxide and/or their agriculturally useful salts for controlling phytopathogenic fungi, or to a method for combating phytopathogenic harmful fungi, which process comprises treating the fungi or the materials, plants, the soil or seeds to be protected against fungal attack, with an effective amount of at least one compound of formula I or an N- oxide or an agriculturally acceptable salt thereof; and to agrochemical compositions comprising at least one such compound and to agrochemical compositions further comprising seeds.

  本发明涉及使用式I的新颖噁二唑或其N-氧化物和/或其对植物病原真菌具有农业用途的盐来控制植物病原真菌，或者涉及用一种式I化合物或其N-氧化物或其农业上可接受的盐的有效量来对抗植物病原有害真菌的方法，该方法包括用至少一种式I化合物或其N-氧化物或其农业上可接受的盐的有效量处理真菌或需要受到真菌侵害保护的材料、植物、土壤或种子；以及包含至少一种这样的化合物的农药组合物，以及进一步包含种子的农药组合物。
• [EN] PURINE DERIVATIVES AS ADENOSINE AL RECEPTOR LIGANDS<br/>[FR] DÉRIVÉS DE PURINE COMME LIGANDS DES RÉCEPTEURS A1 À L'ADÉNOSINE
  申请人：NOVARTIS AG

  公开号：WO2009050199A1

  公开（公告）日：2009-04-23

  Compounds of formula (I), their preparation and use as pharmaceuticals (I), wherein X, Y, and Z are as defined herein.

  公式（I）的化合物，其制备和用途作为药物（I），其中X、Y和Z的定义如下。
• Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20030105111A1

  公开（公告）日：2003-06-05

  The present invention is directed to a compound of Formula I: 1 wherein A, R 1 , and R 2 are defined herein. The present invention is also directed to compositions comprising compounds of Formula I, methods of using compounds of Formula I, and methods of making compounds of Formula I.

  本发明涉及一种具有以下结构的化合物：其中A、R1和R2在此处被定义。本发明还涉及包含Formula I化合物的组合物、使用Formula I化合物的方法以及制备Formula I化合物的方法。
• FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF
  申请人：Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

  公开号：EP3444250A1

  公开（公告）日：2019-02-20

  The present invention relates to an FGFR4 inhibitor having a structure represented by formula (I), preparation method therefor, and applications thereof. A series of compounds represented by formula (I) in the present invention have a very-strong inhibition effect on the activity of FGFR4 kinase, has very-high selectivity, can be widely used in the preparation of drugs for treating cancers, specially a liver cancer, a stomach cancer, a prostate cancer, a skin cancer, an ovarian cancer, a lung cancer, a breast cancer or a colon cancer, and can be developed into a new-generation FGFR4 inhibitor drug.

  本发明涉及一种具有式（I）结构的FGFR4抑制剂、其制备方法及其应用。本发明中式（I）代表的一系列化合物对FGFR4激酶的活性有很强的抑制作用，具有很高的选择性，可广泛用于制备治疗癌症，特别是肝癌、胃癌、前列腺癌、皮肤癌、卵巢癌、肺癌、乳腺癌或结肠癌的药物，并可开发成新一代FGFR4抑制剂药物。